Phase I multiple-center, open-label, dose escalation and dose expansion study for assessing the safety, tolerability, pharmacokinetics and anti-tumor effect of PLB1004 in treatment of advanced non-small cell lung cancer
2022-09-26
View Details >
Vebreltinib PLB1004

China headquarters: 5th Floor, Block B, Wangjing Science and Technology Park, Lize Middle 2nd Road, Chaoyang District, Beijing.
American branch: 850 New Burton Road, Suite 201, City of Dover,County of Kent, State of Delaware
Phone: 010- 84148921
Email:
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.

京ICP备2020040683号-2